Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Enveda raised a $311 million Series E at a $2 billion valuation to advance AI-discovered, nature-derived drugs into trials.
1 stories, newest first · one card per story
Enveda raised a $311 million Series E at a $2 billion valuation to advance AI-discovered, nature-derived drugs into trials.
Today 1.6K readers · 2.5K views · 779 reads · all time 189K views